

INDEX

A

- ABCB1, 61
 Abiraterone, 329
 Absorption
 - of aminoglycosides, 125
 - of antirejection agents, 209–210
 - of carbamazepine, 225–226
 - of ethosuximide, 251
 - of fosphenytoin, 335
 - geriatric differences in, 85
 - of lithium, 303
 - pediatric age-dependent differences in, 66
 - pediatric intramuscular route and, 68
 - pediatric oral route and, 67–68
 - pediatric percutaneous route and, 68
 - pediatric rectal route and, 68
 - of phenobarbital, 324
 - of phenytoin, 334–335
 - of theophylline, 352
 - of unfractionated heparin, 258–259
 - of valproate, 366–367
 - of vancomycin, 379
 - of warfarin, 405
 Acarbose, 98, 417
 ACE (angiotensin-converting enzyme)
 - inhibitors
 - antirejection agents and, 219
 - geriatric patient and, 84, 90
 - lithium and, 312
 Acetaminophen
 - carbamazepine and, 232
 - geriatric patient and, 98
 - pediatric patient and, 72, 73
 - warfarin and, 416
 Acetazolamide, 88, 90, 233
 Actual body weight, 41
 Acute kidney injury, 23
 - renal function quantification of, 24
 - vancomycin and, 393
 Acute myocardial infarction, 295
 Acyclovir
 - aminoglycosides and, 144
 - antirejection agents and, 218
 - renal function and, 28, 34
 Adjusted body weight, 44
 Adolescence, 65, 166. *See also* Pediatrics
 Advanced age, 295, 415. *See also* Geriatrics
 Adverse drug reactions, 84–85
 AFFIRM, 246
 Albiglutide, 98
 Alcohol use/alcoholism
 - antidepressants and, 167
 - by geriatric patient, 89
 - liver disease and, 167
 - warfarin and, 416, 418
 Alendronate, 98
 Allopurinol
 - antirejection agents and, 217, 219
 - theophylline and, 360
 - warfarin and, 416
 Alprazolam, 88, 92, 98
 Aluminum/magnesium hydroxide, 219
 Amantadine
 - geriatric patient and, 90, 98
 - renal function and, 28, 34
 Amantadine + quinidine interaction, 25
 American Academy of Neurology, 195
 American Academy of Pediatrics, 296
 American College of Chest Physicians, 410
 American Epilepsy Society, 195
 American Geriatrics Society, 91, 92
 American Society for Blood and Marrow Transplantation, 50
 American Society of Clinical Oncology, 49
 Amikacin, 123
 - distribution of, 127
 - dosage forms of, 125
 - dosing interval for, 132
 - geriatric patient and, 98

- pediatric patient and, 74, 75, 76
- pregnancy and, 146
- renal function and, 34
- Amiloride**, 9
- Aminoglutethimide**, 416
- Aminoglycoside(s)**, 123–153
 - antirejection agents and, 219
 - body weight and, 46
 - dosage forms of, 124–126
 - dosage range for, 123–124
 - dosing strategies for, 129–135
 - drug concentration monitoring for, 3, 6
 - drug–drug interactions for, 144
 - geriatric patient and, 90
 - pediatric patient and, 69, 70, 71, 72, 75–76
 - pharmacodynamic monitoring of, 142–144
 - pharmacogenomics and, 146
 - pharmacokinetics of, 126–128
 - renal function and, 27, 32
 - therapeutic ranges for, 135–141
 - warfarin and, 416
- Aminophylline**, 98, 352
- Amiodarone**
 - antirejection agents and, 219
 - geriatric patient and, 93
 - lidocaine and, 294
 - phenytoin and, 343
 - warfarin and, 416
- Amiodipine**, 99
- Amitriptyline**
 - antidepressants and, 156–161, 163–164
 - geriatric patient and, 87, 88, 99
- Ammonium chloride**, 25
- Amoxapine**, 157–161, 164
- Amoxicillin**, 28, 34, 99
- Amphetamines**, 25, 93
- Amphotericin**, 28, 34
- Amphotericin B**
 - aminoglycosides and, 144
 - antirejection agents and, 219
 - vancomycin and, 392
- Ampicillin**
 - geriatric patient and, 99
 - pediatric patient and, 67
 - renal function and, 28, 34
- Ampicillin/sulbactam**, 34
- Amputations**, 15
- Anderson, Douglas M.**, 323–332
- Androgens**, 417
- Angiotensin receptor blockers (ARBs)**, 312
- Anorexic agents**, 93
- Antacids**, 218, 343
- Antibiotics**
 - antirejection agents and, 219
 - drug concentration monitoring of, 3
 - lithium and, 312
- Anticoagulants**, 232
- Anticonvulsants**
 - antirejection agents and, 219
 - geriatric patient and, 85
 - lithium and, 312
- Antidepressants**, 61, 155–171
 - carbamazepine and, 232
 - dosage forms of, 156, 158
 - dosing strategies for, 160–162
 - drug–disease state/condition and, 166–168
 - geriatric patient and, 91
 - oral dosage ranges for, 157
 - pharmacodynamic monitoring of, 166, 167
 - pharmacokinetics of, 156, 160
 - therapeutic monitoring of, 165–166
 - therapeutic range for, 162–163, 164
 - therapeutic response of, 164–165
 - usual dosage range for, 156
- Antidiabetics**, 85
- Antiepileptics**, 61, 173–203
 - carbamazepine and, 232
 - dosage forms of, 174
 - drug concentration monitoring of, 5
 - generic substitution of, 196
 - use of newer, 195
- Antifungals**, 219, 232, 233
- Antihypertensives**, 91
- Antiparkinson drugs**, 91
- Antipsychotics**
 - carbamazepine and, 232
 - geriatric patient and, 91
 - lithium and, 312
- Antirejection agents**, 205–222
 - bioavailability of, 210
 - clearance values for, 212–213
 - dosage forms of, 206, 208
 - dosage range for, 206–208
 - drug–drug interactions of, 217–218, 219
 - genes affecting, 220
 - molecular weights of, 220
 - pharmacodynamic monitoring of, 215–216, 217
 - pharmacokinetics of, 209–213
 - protein binding of, 211
 - therapeutic monitoring of, 215
 - therapeutic range for, 214

- Apixaban
 geriatric patient and, 91, 99
 phenobarbital and, 329
 renal function and, 28
- Apremilast, 329
- Aprepitant, 219, 416
- Arbekacin, 123, 124
- Area under the curve, 386, 389–390
- Aripiprazole
 geriatric patient and, 99
 phenobarbital and, 329
- Ascites, 144
- Ascorbic acid, 416
- Asphyxia, 71–72
- Aspirin
 geriatric patient and, 93, 99
 heparin and, 271
 valproate and, 372
- Aspirin/acetylated salicylates, 417
- Assay issues
 with aminoglycosides, 141
 with digoxin, 245, 246
 with lithium, 311
 with low molecular weight heparin, 274
 with phenobarbital, 326
 with unfractionated heparin, 266
 with vancomycin, 395
- Asthma, 357, 359
- Atazanavir, 329
- Atenolol, 29, 34, 99
- Atomoxetine, 76
- Atorvastatin, 218
- ATP-binding cassette (ABC), 57, 58, 59
- Atropine, 88
- Azathioprine
 antirejection properties of, 205–206,
 209–213, 216–220
 geriatric patient and, 99
 warfarin and, 416
- Azithromycin, 99
- Azole antifungals, 416
- Aztreonam, 29, 34
-
- B**
- Bacitracin, 144
- Bainbridge, Jacquelyn L., 173–203, 223–238,
 251–256
- Barbiturates
 ethosuzimide and, 255
 geriatric patient and, 89, 91, 93
 warfarin and, 416
- Bedaquiline, 329
- Beers Criteria, 91–92
- Belladonna alkaloids combination, 93
- Benazepril, 29, 34, 88, 99
- Benzathine penicillin G, 66
- Benzodiazepines
 carbamazepine and, 232
 geriatric patient and, 89, 91
 phenobarbital and, 329
- Benzylpenicillin + probenecid interaction, 25
- Bepridil, 27
- Beta-adrenergic antagonists/blockers, 294, 312
- Beta-agonists, 91
- Beta-blockers
 carbamazepine and, 232
 geriatric patient and, 89, 91
 phenobarbital and, 329
 theophylline and, 360
- Beta-lactams
 aminoglycosides and, 144
 drug concentration monitoring of, 3
 pediatrics and, 69, 76
- Bicarbonate, 329
- Bioavailability, 304, 324
- Biotransformation, 26
- Birth age, 65
- Bisoprolol, 29, 34
- Bleomycin, 99
- Blood–brain barrier, 57, 59
- Boceprevir, 219, 329
- Body
 composition changes of, 41–43
 mass index, 41
- Body size descriptor, 42, 43–45, 49
 equations for, 42
 output examples of, 44
- Body weight, 14–15
- Bosentan, 416
- Bromocriptine, 219
- Broth microdilution method, 385
- Bumetanide, 74
- Buprenorphine, 329
- Bupropion
 antidepressants and, 157–161, 164–165,
 167–168
 geriatric patient and, 99

Burns, 144
 Buspirone, 100
 Busulfan, 100

C

- Caffeine, 351, 355
 geriatric patient and, 88
 lithium and, 312, 314
 pediatric patient and, 72
 theophylline and, 360
- Calcineurin inhibitors, 329
- Calcium, 86
- Calcium channel blockers
 antirejection agents and, 219
 geriatric patient and, 89, 91
 lithium and, 312
 phenobarbital and, 329
 theophylline and, 360
- Candesartan, 100
- Capecitabine, 416
- Capreomycin, 144
- Captopril, 100
- Carbamazepine, 223–238
 antiepileptic properties of, 173–174, 178–179,
 182–184, 187, 189, 193
 dosage forms of, 224
 dosage range for, 223–224
 dosing strategies for, 228–229
 drug–disease state/condition and, 232–233
 drug–drug interactions and, 231–232, 233
 ethosuzimide and, 255
 pharmacodynamic monitoring of, 230–231
 pharmacokinetics for, 225–228
 phenobarbital and, 329
 phenytoin and, 343
 theophylline and, 360
 therapeutic monitoring of, 229–230
 therapeutic range for, 229
 valproate and, 372, 373
 warfarin and, 416
- Carbapenems, 372
- Carbenoxolone, 88
- Carbidopa, 109
- Carboplatin, 144, 417
- Cardiac disease, 167–168
- Cardiac valve replacement, 419
- Cardiology, 60–61
- Carisoprodol, 93
- Carson, Stanley W., 301–321
- Carvedilol, 329
- Casposungin, 219
- Cefaclor, 100
- Cefamandole, 100
- Cefazolin
 geriatric patient and, 100
 renal function and, 29, 34
- Cefdinir, 100
- Cefepime
 geriatric patient and, 100
 renal function and, 29, 34, 36
- Cefixime, 100
- Cefoperazone, 101
- Cefotaxime, 29
- Cefotetan, 101
- Cefoxitin, 29
- Cefpodoxime, 101
- Cefprozil, 101
- Ceftaroline, 29, 34
- Ceftazidime
 geriatric patient and, 101
 renal function and, 29, 34
- Ceftolozane/tazobactam, 29
- Ceftriaxone
 geriatric patient and, 88
 renal function and, 34
- Cefuroxime
 geriatric patient and, 101
 IV, renal function and, 29
- Celecoxib
 geriatric patient and, 101
 lithium and, 314
 warfarin and, 416
- Ceotaxime, 101
- Cephalexin, 29, 34
- Cephalosporins
 aminoglycosides and, 144
 renal function and, 27
 warfarin and, 416
- Cetirizine, 29
- Charcoal, 329, 360
- Chemotherapy, 49–50
- Child/children, 65, 134–135. *See also* Pediatrics
- Chloral hydrate, 416
- Chlorambucil, 101
- Chloramphenicol
 antirejection agents and, 219
 pediatric patient and, 66

- phenobarbital and, 329
- phenytoin and, 343
- warfarin and, 416
- Chlordiazepoxide, 87, 88, 89, 92, 101
- Chloroquine, 88
- Chlorpheniramine, 93, 329
- Chlorpromazine
 - carbamazepine and, 231
 - geriatric patient and, 88, 101
 - phenobarbital and, 329
- Chlorpropamide, 90, 92, 102
- Chlorzoxazone, 93
- Cholestyramine, 102, 416
- Chronic kidney disease (CKD), 23
 - drug dosing for, 27–28
 - drugs with reduced nonrenal clearance and, 26
 - maintenance dosages for, 28–31
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), 11, 12, 13, 23
- Chronic renal insufficiency, 16
- Cidofovir, 25, 29, 34
- Cimetidine
 - antiepileptics and, 183
 - antirejection agents and, 219
 - carbamazepine and, 233
 - creatinine clearance and, 9, 16
 - geriatric patient and, 87, 90, 102
 - lidocaine and, 294
 - phenytoin and, 343
 - renal function and, 29, 34
 - theophylline and, 360
 - valproate and, 372
 - warfarin and, 416
- Cimetidine + itraconazole, 25
- Ciprofloxacin
 - antirejection agents and, 219
 - geriatric patient and, 102
 - lidocaine and, 294
 - phenytoin and, 343
 - renal function and, 29, 34
- Ciprofloxacin + probenecid interaction, 25
- Cirrhosis, 144
- Cisapride, 102
- Cisplatin
 - aminoglycosides and, 144
 - antirejection agents and, 219
 - carbamazepine and, 233
 - geriatric patient and, 102
 - lithium and, 314
- Citalopram
 - antidepressants and, 157–161, 164–165, 167
 - geriatric patient and, 102
- Clarithromycin
 - carbamazepine and, 233
 - geriatric patient and, 102
 - renal function and, 29, 34
 - theophylline and, 360
- Clearance
 - of aminoglycosides, 129–130
 - of carbamazepine, 227
 - of digoxin, 242–243
 - of ethosuximide, 253
 - of lidocaine, 289, 290
 - of lithium, 305–306
 - of phenobarbital, 325
 - of phenytoin, 337–338
 - of theophylline, 355
 - of valproate, 368–369
 - of vancomycin, 380
- Clindamycin, 66
- Clinical and Laboratory Standards Institute (CLSI), 142, 385
- Clobazam
 - antiepileptic properties of, 173–174, 191–193
 - valproate and, 373
- Clofibrate, 417
- Clomethiazole, 88
- Clomipramine
 - antidepressants and, 157–159, 161, 164
 - carbamazepine and, 231, 232
 - phenobarbital and, 329
- Clonidine, 92, 102
- Clopidogrel, 60
- Clopidogrel/ticlopidine, 417
- Clorazepate, 86, 89, 92, 102
- Cloxacillin, 76
- Clozapine, 329
- CNS depression, 342
- Coagulation tests, 266
- Cobicistat, 329
- Cockcroft-Gault equation, 11, 14, 18, 23, 46–48
- Codeine, 72, 76
- Colchicine, 218, 219
- Colestipol, 102, 416
- Colistin, 34, 144
- Concentration measurement frequency
 - for aminoglycosides, 136
 - for lithium, 309–310

- Concentration-related efficacy
 - of aminoglycosides, 142
 - of antirejection agents, 215
 - of carbamazepine, 230
 - of digoxin, 245
 - of ethosuximide, 254
 - of lithium, 311–312
 - of low molecular weight heparin, 274–275
 - of phenobarbital, 327
 - of phenytoin, 341
 - of theophylline, 358–359
 - of unfractionated heparin, 268
 - of valproate, 371–372
 - of vancomycin, 386
 - Concentration-related toxicity
 - of aminoglycosides, 142–144
 - of antirejection agents, 215
 - of carbamazepine, 230–231
 - of digoxin, 245
 - of ethosuximide, 254
 - of lidocaine, 293
 - of lithium, 311–312, 313
 - of low molecular weight heparin, 275
 - of phenytoin, 341
 - of theophylline, 359–360
 - of unfractionated heparin, 268–269
 - of vancomycin, 390–391
 - Congestive heart failure, 419
 - Continuous infusion dosing, 382, 384
 - Continuous renal replacement therapies (CRRT), 23, 24, 31, 33–37, 393–395
 - COPD (chronic obstructive pulmonary disease), 359
 - Corticosteroids
 - antirejection agents and, 206, 214, 216
 - carbamazepine and, 232
 - phenobarbital and, 329
 - theophylline and, 360
 - warfarin and, 416, 417
 - Cotrimoxazole, 219
 - Creatinine assays
 - compounds that interfere with, 10
 - standardization of, 10
 - Creatinine clearance, 46–48
 - amputations and, 15
 - in chronic renal insufficiency, 16
 - dialysis and, 16
 - estimating, 9–21
 - formulas to estimate in adults, 11–13
 - geriatric patient and, 15, 90
 - liver disease and, 16
 - pediatric patient and, 16–17, 70
 - spinal cord injury and, 16
 - time to steady state and, 18
 - underweight patients and, 15
 - unstable renal function and, 18–19
 - Creatinine production, 14
 - Critically ill, phenytoin and, 345
 - Cropps, Cheryl D., 55–63
 - Cyclobenzaprine, 93
 - Cyclophosphamide, 103, 417
 - Cyclosporine
 - antirejection properties of, 205–206, 208–220
 - phenytoin and, 342
 - warfarin and, 416
 - CYP2C9, 60, 61
 - CYP2C19, 60, 61
 - CYP2D6, 61
 - Cyproheptadine, 93
 - Cystic fibrosis, 75–76, 145
 - Cytochrome P 450 enzyme, 57–58, 89
-
- D**
- Dabigatran, 92, 260, 273, 274
 - Daclatasvir, 329
 - Dager, William E., 257–283
 - Dalteparin, 272, 275
 - Danazol, 233
 - Daptomycin, 29, 34
 - Daunorubicin, 103
 - Delavirdine, 416
 - Depakote, 366
 - Desipramine
 - antidepressants and, 157–161, 163–164
 - geriatric patient and, 87, 88, 103
 - Desmethyl diazepam, 88
 - Dessicated thyroid, 93
 - Desvenlafaxine, 157–159, 161, 164, 167
 - Dexchlorpheniramine, 93
 - Diabigatran etexilate, 103
 - Dialysis
 - aminoglycosides and, 145
 - creatinine clearance in, 16
 - vancomycin and, 393–394
 - Diapagliflozin, 103
 - Diazepam
 - geriatric patient and, 88, 89, 92, 103
 - lithium and, 312

- pediatric patient and, 66, 68, 71, 72
 - pharmacogenomics and, 61
- Dibekacin, 123
- Diclofenac
 - geriatric patient and, 93, 103
 - lithium and, 314
- Dicloxacillin, 416
- Dicyclomine, 93
- Didanosine, 29, 34
- DiDomenico, Robert, 239–250
- Diflunisal, 87, 88, 93, 103
- Digitalis glycosides, 85
- Digitalis Investigation Group trial, 245
- Digoxin, 239–250
 - antiepileptics and, 179
 - antirejection agents and, 218, 219
 - assay issues for, 245, 246
 - carbamazepine and, 232
 - dosage forms of, 240–241
 - dosage range for, 239–240
 - dosing strategies for, 242–244
 - drug–disease state/condition and, 248
 - drug–drug interactions with, 247–248
 - geriatric patient and, 86, 90, 93, 103
 - half life of, 241–242
 - lithium and, 312
 - maintenance dosages, interval adjustments for, 240
 - pediatric patient and, 66, 67, 68
 - pharmacodynamic monitoring of, 245–246
 - pharmacokinetics of, 241–242
 - phenobarbital and, 329
 - renal function and, 27
 - therapeutic monitoring of, 244–245
 - time to steady state of, 241–242
- Digoxin + itraconazole, 25
- Digoxin + ritonavir, 25
- Diltiazem, 103
- Diphenhydramine, 93, 104
- Dipyridamole, 92
- Direct thrombin inhibitors, 417
- Disopyramide
 - geriatric patient and, 88, 90, 93
 - lidocaine and, 289
 - phenobarbital and, 329
 - renal function and, 27
- Distribution
 - of aminoglycosides, 126–127
 - of antirejection agents, 210–211
 - of carbamazepine, 226
 - of ethosuximide, 252
 - in geriatric patient, 85
 - of lidocaine, 287
 - of lithium, 304
 - pediatric age-dependent differences in, 66
 - in pediatric patient, 69
 - of phenobarbital, 324–325
 - of phenytoin, 335–337
 - of theophylline, 352–353, 354
 - of unfractionated heparin, 259
 - of valproate, 367
 - of warfarin, 406
- Disulfiram
 - phenytoin and, 343
 - theophylline and, 360
 - warfarin and, 416
- Diuretics
 - antirejection agents and, 218
 - lithium and, 312
- Dolutegravir, 329
- Donepezil
 - geriatric patient and, 84, 88, 104
 - phenobarbital and, 329
- Donnelley, Monica A., 377–401
- Doripenem, 29
- Dosage
 - continuous renal replacement therapies and, 33–37
 - hemodialysis adjustments in, 32–33
 - and interval estimates, aminoglycosides, 130–131
 - proportionality in obesity, 48–49
 - valproate adjustment and, 369–370
- Dosage forms
 - of antidepressants, 156
 - of carbamazepine, 224
 - of ethosuximide, 252
 - of fondaparinux, 278
 - of fosphenytoin, 334, 335
 - of lidocaine, 285–287
 - of lithium, 303
 - of low molecular weight heparin, 272–273
 - of phenobarbital, 324
 - of phenytoin, 334, 335
 - of theophylline, 352, 354
 - of unfractionated heparin, 258
 - of valproate, 365, 366
 - of vancomycin, 378–379
 - of warfarin, 404–405
- Dosage range
 - of antidepressants, 156
 - of antirejection agents, 206–208

- of digoxin, 239–240
- of ethosuximide, 251
- of fondaparinux, 277
- of lidocaine, 285, 286
- of low molecular weight heparin, 272
- of phenobarbital, 323
- of unfractionated heparin, 257–258
- of valproate, 365
- of vancomycin, 377–378
- of warfarin, 404
- Dose titration
 - down, 7
 - up, 6–7
- Dosing strategies
 - for aminoglycosides, 129–135
 - for antidepressants, 160–162
 - for carbamazepine, 228–229
 - for digoxin, 242–244
 - for ethosuximide, 253
 - for lidocaine, 289–292
 - for lithium, 306–307
 - for low molecular weight heparin, 273–274
 - for obese patients, 49–51
 - for theophylline, 356–357
 - for unfractionated heparin, 260–
 - for valproate, 369–370
 - for vancomycin, 381–385
 - for warfarin, 407–410
- Dosing weight
 - for aminoglycosides, 129
 - for vancomycin, 377
- Dowling, Thomas C., 23–39
- Doxazosin, 92
- Doxycycline, 27
- Doxepin
 - antidepressants and, 157–159, 161, 164
 - geriatric patient and, 92, 104
 - Doxorubicin
 - carbamazepine and, 233
 - geriatric patient and, 104
 - phenobarbital and, 330
- Doxycycline, 232, 312
- Dronedaron, 93, 330
- Droxidopa, 104
- Drug clearance mechanisms
 - nonrenal, 26–27
 - renal drug transporters and, 25
 - renal elimination, 24–25
- Drug concentration monitoring, 3–8
 - adherence and, 5–6
 - decision-making process for, 3–5
 - drug selection for, 3
 - efficacy and, 5, 6
 - toxicity and, 5, 6
- Drug disposition, 71–73
- Drug dosing
 - for chronic kidney disease patients, 27–28
 - for overweight, obese patients, 41–53
 - for pediatric patients, 65–81
 - renal concepts and, 23–39
- Drug membrane transporters, 59
- Drug metabolizing enzymes, 59
- Drug–disease state/condition interactions
 - aminoglycosides and, 144–146
 - antidepressants and, 166–168
 - carbamazepine and, 232–233
 - digoxin and, 248
 - ethosuximide and, 255
 - fondaparinux and, 278
 - lidocaine and, 294–296
 - lithium and, 312–315
 - low molecular weight heparin and, 273, 276–277
 - phenobarbital and, 330
 - phenytoin and, 343–345
 - theophylline and, 361–362
 - unfractionated heparin and, 264, 270
 - valproate and, 373
 - vancomycin and, 392–395
 - warfarin and, 415, 418–419
- Drug–drug interactions
 - aminoglycosides and, 144
 - antidepressants and, 166, 167
 - antirejection agents and, 217–218, 219
 - carbamazepine and, 231–232, 233
 - digoxin and, 247–248
 - ethosuximide and, 255
 - geriatric patient and, 84
 - lidocaine and, 293–294
 - lithium and, 312–313
 - low molecular weight heparin and, 276
 - phenobarbital and, 328–330
 - phenytoin and, 342–343
 - theophylline and, 360–361
 - unfractionated heparin and, 270, 271
 - valproate and, 372
 - vancomycin and, 391–392
 - warfarin and, 414–415, 416–417
- Duby, Jeremiah J., 377–401
- Dulaglutide
 - geriatric patient and, 104
 - antidepressants and, 157–159, 161, 164–165, 167–168

E

Edoxaban, 104, 260, 273, 274

Efavirenz

- phenobarbital and, 330
- warfarin and, 416

Elderly patients. *See also* Geriatrics

- creatinine in, 15
- lidocaine and, 295

Elimination

- of aminoglycosides, 127–130
- of antirejection agents, 212
- of carbamazepine, 226–228
- of ethosuximide, 252
- geriatric patient and, 89–90
- of lidocaine, 288
- of lithium, 305
- pediatric patient and, 69–71
- of phenytoin, 337–338
- of theophylline, 354–355
- of unfractionated heparin, 259
- of valproate, 368
- of vancomycin, 380
- of warfarin, 406–407

Elvitegravir, 330

EMLA topical agents, 68

Empagliflozin, 104

Enalapril

- geriatric patient and, 88
- renal function and, 29, 34

End-stage renal disease, 23

Enoxaparin, 271, 272, 275

Ensom, Mary H. H., 205–222

Enzalutamide, 330

Enzymatic assay, 10, 17

Epigenetics, 51

Eprosartan, geriatric patient and, 104

EQUIGEN study, 196

Erstad, Brian L., 41–53

Erythromycin

- antiepileptics and, 183
- carbamazepine and, 233
- geriatric patient and, 104
- lidocaine and, 294
- theophylline and, 360

Escitalopram

- antidepressants and, 157–161, 164, 167
- geriatric patient and, 104
- Eslicarbazepine
- antiepileptic properties of, 174, 193–195

- phenobarbital and, 330
- valproate and, 372, 373

Esomeprazole, 105

Estazolam, 92

Estrogens, 93

Eszopiclone, 92

Etest method, 385

Ethacrynic acid, 144

Ethambutol, 90

Ethanol. *See also* Alcohol use/alcoholism

- ethosuzimide and, 255
- geriatric patient and, 105

Ethchlorvynol, 416

Ethinyl estradiol, 86

- antiepileptics and, 178, 183
- antirejection agents and, 218

Ethosuximide, 251–256

- dosage range for, 251
- dosing strategies for, 253
- drug–disease state/condition and, 255
- drug–drug interactions and, 255
- pharmacodynamic monitoring of, 254
- pharmacokinetics of, 251–253
- therapeutic range for, 253
- valproate and, 372

Etodolac, 88, 93, 105

Etomidate, 66

Etoposide

- phenobarbital and, 330
- warfarin and, 417

Etravirine, 330

Exchange transfusion, pediatric, 73

Excretion, 85

Exposure-related toxicity, aminoglycosides, 142–144

Extended-spectrum penicillins, 144

Extracorporeal membrane oxygenation (ECMO), 73–74

Ezetimibe, 105

Ezogabine, 174, 190–191

F

Famciclovir, 29, 34

Famotidine

- creatinine clearance and, 16
- geriatric patient and, 105
- renal function and, 29, 34

Febrile neutropenia, 145

- Febuxostat, 219
- Felbamate
antiepileptic properties of, 173, 174–175
carbamazepine and, 228, 233
geriatric patient and, 84
valproate and, 372, 373
- Felodipine
antiepileptics and, 183
carbamazepine and, 232
geriatric patient and, 105
- Fenofibrate, 417
- Fenopropfen, 93, 105
- Fentanyl
carbamazepine and, 232
geriatric patient and, 86, 88, 105
pediatric patient and, 74
phenobarbital and, 329
- Fexofenadine
geriatric patient and, 106
renal function and, 29, 34
- Fexofenadine + probenecid interaction, 25
- Fibric acid derivatives, 219
- Finley, Patrick R., 155–171
- 5-aminosalicylic acid, 219
- Fluconazole
phenytoin and, 343
renal function and, 34
- Flucytosine, 29
- Fluoroquinolone
renal function and, 27
warfarin and, 416
- Fluorouracil
geriatric patient and, 106
warfarin and, 416
- Fluoxetine
antidepressants and, 156–165, 167
carbamazepine and, 233
geriatric patient and, 106
phenobarbital and, 329
phenytoin and, 343
- Fluoxetine + norfluoxetine, 165
- Fluphenazine, 88
- Flurazepam, 88, 92, 106
- Fluribuprofen,
geriatric patient and, 106
lithium and, 314
- Flutamide, 106
- Fluvastatin
antirejection agents and, 218
geriatric patient and, 106
- Fluvoxamine
antidepressants and, 157–159, 161, 164, 167
carbamazepine and, 233
lidocaine and, 293, 294
phenobarbital and, 329
theophylline and, 360
- Folic acid
geriatric patient and, 86
phenytoin and, 343
- Follow-up concentration measurements,
aminoglycosides, 140
- Fondaparinux, 277–283
dosage forms for, 278
dosage range for, 277
drug–disease/condition interactions for,
278
geriatric patient and, 106
pharmacokinetics of, 278
reversing effect of, 278
therapeutic monitoring of, 278
- Food and Drug Administration (FDA) dosing
guidelines, 12
- Foscarnet, 29, 35
- Fosinopril, 106
- Fosphenytoin, 333–349
dosage forms of, 334, 335
geriatric patient and, 84, 106
pharmacokinetics of, 334
sampling of, 340
warfarin and, 416
- Frailty, 83, 145
- Furosemide
aminoglycosides and, 144
geriatric patient and, 88, 106
renal function and, 27
theophylline and, 360
vancomycin and, 392
-
- G**
- Gabapentin
antiepileptic properties of, 174, 175–176, 177,
186
geriatric patient and, 84, 106
renal function and, 30, 35
valproate and, 372, 373
- Galantamine, 84
- Ganciclovir
antirejection agents and, 219
renal function and, 30, 35
- Gastrointestinal absorption, 26–27. *See also*
Absorption

- Gefitinib, 417
- Gemcitabine, 417
- Gemfibrozil
 - warfarin and, 417
 - geriatric patient and, 107
- Genetic polymorphisms, 60
- Gentamicin, 123
 - concentration monitoring, interval adjustment for, 140
 - distribution of, 127
 - dosage forms for, 125
 - dosing interval for, 132
 - geriatric patient and, 107
 - maintenance dose for, 124
 - nomogram for neonates, 139
 - pediatric patient and, 66, 74, 75
 - pregnancy and, 146
 - renal function and, 35
- Geriatrics
 - age-related changes, drug response in, 90–93
 - antidepressants and, 167
 - elimination in, 89
 - pharmacokinetics in, 98–119
 - physiologic changes in, 85–89
- Gestational age, 65
- Gidal, Barry E., 365–375
- Glimepiride, 107
- Glipizide, 30, 35
- Glomerular filtration rate (GFR), 9, 47
 - factors affecting estimates of, 9–10
 - in pediatric patient, 70
- Glutethimide, 416
- Glyburide
 - antirejection agents and, 218
 - geriatric patient and, 92, 107
 - renal function and, 30
- Glycoprotein IIB/IIIA inhibitors, 417
- Goldstone, Lisa W., 301–321
- Grapefruit juice
 - antirejection agents and, 219
 - carbamazepine and, 233
- Griseofulvin
 - phenobarbital and, 329
 - warfarin and, 416
-
- H**
- H₂-antagonists, 90
- Half life
 - of aminoglycosides, 128, 129, 130
 - of antirejection agents, 213
 - of carbamazepine, 228
 - of digoxin, 241–242
 - of ethosuximide, 253
 - of lidocaine, 289, 290–291
 - of lithium, 305–306
 - of phenobarbital, 326
 - of phenytoin, 339
 - of valproate, 368–369
 - of vancomycin, 381
 - of warfarin, 407
- Haloperidol
 - ethosuximide and, 255
 - geriatric patient and, 88, 107
 - phenobarbital and, 329
- Halothane, 91
- Hart, Felecia M., 173–203, 223–238, 251–256
- Heintz, Brett H., 377–401
- Hemodialysis, 31–32
 - dosage adjustments for, 32–33
 - drugs and, 32
 - ethosuximide and, 255
 - warfarin and, 418–419
- Heparin
 - geriatric patient and, 107
 - size descriptors and, 44–45
 - warfarin and, 417
- Hepatic disease
 - lidocaine and, 295
 - cirrhosis, phenytoin and, 343
- Hepatic dysfunction
 - aminoglycosides and, 145
 - ethosuximide and, 255
- Hepatic insufficiency
 - antidepressants and, 168
 - vancomycin and, 392
- HIV/AIDS, 344
- HMG CoA reductase inhibitors, 329
- Hormonal contraceptives, 232
- Hydralazine, 107
- Hydrochlorothiazide, 107
- Hydrocodone
 - geriatric patient and, 107
 - phenobarbital and, 329
- Hydrocortisone, 206
- Hydroxyurea, 107
- Hydroxyzine, 91, 93
- Hyperdynamic populations, 392
- Hypothermia (therapeutic), 145

I

Ibuprofen
 geriatric patient and, 88, 93, 107
 lithium and, 314
 pediatric patient and, 75

IDMA laboratory-calibrated creatinine, 12–13

IDMS reference method, 10

Ifosfamide
 phenobarbital and, 329
 warfarin and, 416

Imatinib, 219

Imipenem, 26

Imipenem/cilastatin, 35

Imipramine
 antidepressants and, 157–161, 163–164
 geriatric patient and, 87, 88, 89, 108

Imipramine + desipramine, 163

Immediate response, 6

Immunosuppressants, 232

Indinavir
 carbamazepine and, 232
 phenobarbital and, 329

Indomethacin
 geriatric patient and, 92, 108
 lithium and, 314
 pediatric patient and, 75
 vancomycin and, 392

Infant, 65

Inflammatory disease states, 168

Influenza virus vaccine, 417

Inhaled corticosteroids, drug concentration monitoring, 3

Initial dose
 of aminoglycosides, 137–141
 of carbamazepine, 224
 of ethosuximide, 251
 of vancomycin, 377
 of valproate, 369
 of warfarin, 407

INR-related efficacy, 412–413

INR-related toxicity, 413
 reversing, 414

Insulin
 geriatric patient and, 93
 renal function and, 30

Intensive care patients, 145

Interferon, human alpha 2-a and 2-b, 360

International League Against Epilepsy, 173

Intramuscular absorption, 45

Inulin, 75

Iodides, 312

Iothalamate, 75

Irbesartan, 108

Irinotecan, 329

Iron, 86

Isepamicin, 123

Isoniazid
 carbamazepine and, 233
 ethosuximide and, 255
 geriatric patient and, 108
 phenytoin and, 343
 warfarin and, 417

Isotretinoin, 417

Itraconazole
 pediatric patient and, 67
 renal function and, 30

Ivabradine, 329

Ivacaftor, 329

Ixabepilone, 329

J

Jaffe-based assays, 10

Jelliffe equation, 11–12

K

Kanamycin, 123, 146

Ketoconazole, 219

Ketoprofen, 93, 108

Ketorolac
 geriatric patient and, 92
 lithium and, 314

Kiang, Tony K. L., 205–222

Kidney disease, 393–394

Kidney function, clinical assessment of, 23

L

Labetalol, 87, 108

Lacosamide
 antiepileptic properties of, 173–174, 186–187
 carbamazepine and, 231
 geriatric patient and, 84
 valproate and, 372, 373

Lactation
 lidocaine and, 296

- phenytoin and, 344–345
- warfarin and, 415
- Lamivudine, 30, 35
- Lamotrigine
 - antiepileptic properties of, 173–174, 176–178, 183, 187, 189
 - carbamazepine and, 231
 - geriatric patient and, 84, 108
 - valproate and, 372, 373
- Lansoprazole, 108
- Large dose extended interval (LDEI)
 - approaches, 131–132
 - aminoglycoside dosing in children, 134–135
 - aminoglycoside dosing in neonates, 133–134
- Lean body weight, 44
 - to fat ratio, geriatric, 87–88
- Leflunomide, 417
- Levetiracetam
 - antiepileptic properties of, 174, 181–182
 - carbamazepine and, 231
 - geriatric patient and, 84, 108
 - renal function and, 30, 35
 - valproate and, 372, 373
- Levodopa, 86, 87, 109
- Levofloxacin
 - geriatric patient and, 109
 - lithium and, 312
 - renal function and, 30, 35
- Levomilnacipran, 157–161, 167–168
- Levonorgestrel, 183
- Levothyroxine
 - carbamazepine and, 232
 - renal function and, 27
- Lidocaine, 285–299, 333
 - dosage forms of, 285–287
 - dosage range for, 285, 286
 - dosing strategies for, 289–292
 - drug–disease state/condition and, 294–296
 - geriatric patient and, 87, 88, 89, 109
 - pharmacodynamics of, 293
 - pharmacokinetics of, 287–291
 - phenobarbital and, 329
 - sampling times for, 292–293
 - therapeutic range for, 292–293
- Linagliptin
 - geriatric patient and, 109
 - phenobarbital and, 329
- Linezolid
 - pediatric patient and, 69
 - renal function and, 30, 35
- Lisinopril
 - geriatric patient and, 109
 - renal function and, 30
- Lithium, 301–321
 - assay issues of, 311
 - carbamazepine and, 231
 - dosage forms of, 303–304
 - dosage range for, 301–302
 - dosing strategies for, 306–307
 - drug–disease state/condition and, 312–315
 - geriatric patient and, 85, 89, 90, 109
 - pharmacodynamics of, 311–312
 - pharmacokinetics of, 303–306
 - therapeutic monitoring of, 308–310, 311
 - therapeutic range for, 308
- Live vaccines, 218
- Liver disease
 - creatinine clearance in, 16
 - warfarin and, 418
- Loading dose
 - of aminoglycosides, 123–124
 - of digoxin, 239–240
 - obesity and, 50
 - of phenobarbital, 323
 - of phenytoin, 333
 - of theophylline, 352
 - of vancomycin, 378
- Loop diuretics
 - theophylline and, 360
 - vancomycin and, 392
- Loratadine, 109
- Lorazepam
 - geriatric patient and, 88, 89, 92, 109
 - valproate and, 372
- Losartan
 - geriatric patient and, 109
 - phenobarbital and, 329
- Lovastatin
 - antirejection agents and, 218
 - geriatric patient and, 109
- Low molecular weight heparin (LMWH), 260–275
 - assay issues with, 274
 - dosage forms of, 272–273
 - dosage range for, 272
 - dosing strategies for, 273–274
 - drug–disease state/condition and, 272, 276–277
 - drug–drug interactions of, 276
 - pharmacodynamic monitoring of, 274–275
 - pharmacokinetics of, 273
 - reversing effect of, 275

therapeutic monitoring of, 274
 therapeutic range for, 274
 warfarin and, 417

Loxapine, 255

Lurasidone, 329

M

Macitentan, 329

Macrolide antibiotics

phenobarbital and, 329

warfarin and, 417

Maintenance dose

for aminoglycosides, 123–124, 125

for carbamazepine, 224

for digoxin, 239, 240

for lithium, 302

obesity and, 50

for phenobarbital, 323

for phenytoin, 333

for theophylline, 352, 353

for vancomycin, 378

for warfarin, 409

Malabsorption, 344

Malnutrition, 145

Mannitol, 144

Maprotiline

antidepressants and, 157–159, 161, 164

geriatric patient and, 88, 109

Maraviroc, 329

Matthias, Kathryn R., 123–153

McCormack, James P., 3–8

Meclofenamate, 93

Meclofenamic acid, 110

Mefenamic acid

geriatric patient and, 93, 110

lithium and, 312, 314

Megestrol, 93

Meloxicam

geriatric patient and, 93

lithium and, 314

Melphalan

antirejection agents and, 219

geriatric patient and, 110

Membrane transporters, 57

ABC, SLC, 58, 59

Meningitis, 145

Meperidine, 87, 88, 92

Mephenytoin, 61

Mercaptopurine, 416

Mesalamine, 417

Metabolism

geriatric patient and, 85, 89

nonrenal drug clearance and, 26

pediatric patient and, 71–73

theophylline and, 354–355

Metaxalone, 93

Metformin

geriatric patient and, 90, 110

renal function and, 30, 35

Metformin + cimetidine interaction, 25

Methadone

carbamazepine and, 232

geriatric patient and, 88

phenobarbital and, 329

Methicillin

pediatric patient and, 75, 76

renal function and, 30

Methimazole, 416

Methocarbamol, 93

Methotrexate, 88, 90, 110

Methsuximide, 329

Methyldopa

geriatric patient and, 92, 110

lithium and, 312

Methylphenidate, 329

Methylprednisolone, 206, 219

Methyltestosterone, 93

Metoclopramide

antirejection agents and, 219

geriatric patient and, 91, 93, 110

phenobarbital and, 329

renal function and, 30, 35

Metoprolol

geriatric patient and, 87, 88, 110

renal function and, 26

Metronidazole

antirejection agents and, 218

geriatric patient and, 87

lithium and, 312

renal function and, 30, 35

warfarin and, 417

Metropenem, 30, 35

Mexifetine, 361

Mexiletine, 294

Midazolam

geriatric patient and, 88

pediatric patient and, 72, 74

Mifepristone, 329
 Miglitol, 110
 Miller, Susan W., 83–119
 Mineral oil, 93
 Minocycline, 312
 Mirabegron, 110
 Mirtazapine
 antidepressants and, 157–161, 164, 167–168
 geriatric patient and, 110
 Misoprostol, 111
 Mitotane, 416
 Modification of Diet in Renal Disease (MDRD)
 equation, 11, 12, 23, 47
 abbreviated, 12–13
 Moexipril, 84, 111
 Molecular weights, 220
 Monamine oxidase (MAO) inhibitor, 156, 231
 Monitoring, of drug concentration, 3–8
 Morbid obesity, lidocaine and, 295
 Morphine
 geriatric patient and, 89, 111
 pediatric patient and, 72, 74
 Murphy, John E., 123–153, 351–364
 Mycophenolate, 205–206, 209–213, 216–220

N

Nabumetone, 93, 111
 Nadolol, 88, 111
 Nafcillin
 antirejection agents and, 219
 warfarin and, 416
 Nahata, Milap C., 65–81
 Nalidixic acid, 67
 Naloxegol, 329
 Naproxen
 geriatric patient and, 87, 88, 93, 111
 lithium and, 314
 valproate and, 372
 Narcotic analgesics, 89, 91
 Nateglinide, 111
 National Asthma Education and Prevention
 Program, 357
 National Institutes of Health, 10
 National Kidney Disease Education Program
 (NKDEP), 10, 12
 Nefazodone
 antirejection agents and, 219

antidepressants and, 161, 164
 carbamazepine and, 233
 geriatric patient and, 111
 Nelfinavir, 329
 Neomycin, 123
 Neonates, 65
 aminoglycoside dosing in, 133–134
 apnea or bradycardia in, 357, 359
 gentamicin nomogram for, 139
 ventilator weaning of, 357
 Nephrotoxicity, 25
 Netilmicin, 123
 Netupitant, 329
 Neuromuscular blocking agents, 312
 Niacinamide, 233
 Nicardipine, 111
 Nifedipine
 antirejection agents and, 218
 geriatric patient and, 92, 111
 Nisoldipine, 111
 Nitrazepam, 88
 Nitrofurantoin, 93
 Nitroglycerin
 geriatric patient and, 111
 heparin and, 271
 Nizatidine
 geriatric patient and, 112
 renal function and, 30
 Nonconcentration-related toxicity
 antirejection agents and, 216
 digoxin and, 246
 phenytoin and, 342
 vancomycin and, 391–392
 Non-dihydropyridine calcium channel blockers,
 233
 Nonrenal clearance, obesity and, 48
 Nonsteroidal anti-inflammatory drugs
 (NSAIDs)
 antirejection agents and, 219
 digoxin and, 248
 geriatric patient and, 84, 87
 heparin and, 271
 lithium and, 312, 314
 warfarin and, 417
 Norepinephrine reuptake inhibitors (NRIs), 155
 Norfluoxetine, 160, 165
 Nortriptyline
 antidepressants and, 157–161, 163–164
 geriatric patient and, 88, 89, 112

Nutritional status
 antidepressants and, 168
 warfarin and, 419
 Nystagmus, 342

O

Obesity, 14
 aminoglycosides and, 145
 body composition changes in, 41–43
 genetic, genomic considerations in, 50–51
 oral absorption in, 45
 pharmacokinetic considerations in, 45
 phenytoin and, 344
 prevalence of, 41
 renal clearance and, 46–47
 vancomycin and, 392
 Octreotide, 219
 Ofloxacin, 35
 Olanzapine
 geriatric patient and, 112
 phenobarbital and, 329
 Olaparib, 330
 Olmesartan
 geriatric patient and, 112
 renal function and, 30
 Omeprazole
 carbamazepine and, 233
 geriatric patient and, 112
 warfarin and, 417
 Oncology, pharmacogenomics and, 60
 Ondansetron, 330
 Opioids
 geriatric patient and, 83–84
 lithium and, 312
 Oral contraceptives
 antiepileptics and, 178, 179, 189
 antirejection agents and, 218, 219
 phenobarbital and, 330
 phenytoin and, 342
 valproate and, 372
 Orlistat
 antirejection agents and, 218
 warfarin and, 417
 Orphenadrine, geriatric patient and, 93
 Overweight, 41
 Oxaprozin, 93, 112
 Oxazepam, 88, 89, 92, 112
 Oxcarbazepine
 geriatric patient and, 84

renal function and, 30
 valproate and, 373

Oxybutynin, 112
 Oxycarbazepine, 174, 182–184, 187, 193
 Oxycodone, 112

P

Pachorek, Robert E., 9–21
 Paclitaxel, 417
 Page II, Robert L., 239–250
 Pai, Vinita B., 65–81
 Palbociclib, 330
 Pancreatitis, 145
 Pancuronium bromide, 232
 Panobinostat, 330
 Pantoprazole, 112
 Paritaprevir, 330
 Paromomycin, 123
 Paroxetine
 antidepressants and, 157–159, 161–162,
 164–165, 167–168
 geriatric patient and, 112
 Patent ductus arteriosus, 74–75, 145
 Peak concentration
 of aminoglycoside, 136–137
 of vancomycin, 386
 Pediatrics
 absorption and, 67–68
 age-dependent differences in Phase I drug
 metabolism, 72
 age-dependent differences in Phase II drug
 metabolism, 73
 age-dependent differences in physiologic
 functions, drug disposition, 66
 classifications in, 65
 creatinine clearance in, 16–17
 distribution and, 69
 drug dosing in, 65–81
 ECMO and, 73–74
 exchange transfusions for, 73
 pharmacogenomics in, 76
 population parameters in vancomycin
 dosing for, 385
 therapeutic vancomycin targets for,
 384–385
 vancomycin dosing for, 384
 Penicillin derivatives, 76
 Penicillin G
 geriatric patient and, 112

- renal function and, 30
- Penicillins
 - antirejection agents and, 218
 - geriatric patient and, 88
 - renal function and, 27
- Pentamidine, 30
- Pentazocine, 92
- Peramivir, 113
- Perampanel
 - antiepileptic properties of, 173–174, 193–194
 - phenobarbital and, 330
 - valproate and, 372, 373
- Perindopril, 113
- P-glycoproteins, 89
- Phan, Hanna, 351–364
- Pharmacodynamic changes, age-related, to drug response, 90–93
- Pharmacodynamics, 55, 56
 - of aminoglycosides, 142–144
 - of antidepressants, 166, 167
 - of carbamazepine, 230–231
 - of digoxin, 245–246
 - of ethosuximide, 254
 - of lidocaine, 293
 - of lithium, 311–312
 - of phenobarbital, 327–328
 - of phenytoin, 341–342
 - of theophylline, 358–359
 - of unfractionated heparin, 268–270
 - of valproate, 371–372
 - of warfarin, 412–413
- Pharmacogenetics, 55
 - history of, 56–57
- Pharmacogenomics, 55–63
 - aminoglycosides and, 146
 - history of, 56–57
 - pediatrics and, 76
 - phenytoin and, 338–339
 - special populations and, 59–60
 - therapeutic examples of, 60–61
- Pharmacokinetics, 55, 56
 - of antidepressants, 156–157
 - of antirejection agents, 209–213
 - of carbamazepine, 225–228
 - of digoxin, 241–242
 - of ethosuximide, 251–253
 - of fondaparinux, 278
 - of lidocaine, 287–291
 - of lithium, 303–306
 - of low molecular weight heparin, 273
 - of phenobarbital, 324–326
 - of phenytoin, 334–339
 - of theophylline, 352–353
 - of unfractionated heparin, 261–264
 - of valproate, 366–370
 - of vancomycin, 379–381
 - of warfarin, 405–407
- Pharmacology, 55
- Phenelzine, 157–160, 164
- Phenobarbital, 323–332
 - antiepileptic properties of, 173, 178, 183, 187, 189
 - carbamazepine and, 228, 233
 - dosage forms of, 324
 - dosage range for, 323
 - drug–disease state/condition and, 330
 - drug–drug interactions and, 328–330
 - geriatric patient and, 88, 93, 113
 - half-life of, 326
 - pediatric patient and, 71
 - pharmacokinetics of, 324–326
 - phenytoin and, 343
 - renal function and, 25
 - theophylline and, 361
 - time to steady state for, 326
 - valproate and, 372, 373
- Phenothiazines
 - ethosuzimide and, 255
 - geriatric patient and, 89, 91
- Phenylbutazone, 314
- Phenytoin, 333–349
 - antiepileptic properties of, 173–174, 178–179, 183–184, 187, 189, 193
 - carbamazepine and, 228, 231, 232, 233
 - dosage forms of, 334, 335
 - dosage range for, 333
 - drug concentration monitoring of, 3, 6
 - drug–disease state/condition and, 343–345
 - drug–drug interactions and, 342–343
 - ethosuzimide and, 255
 - geriatric patient and, 84, 88, 113
 - nonconcentration-related side effects of, 342
 - pediatric patient and, 66, 69, 71, 72
 - pharmacodynamics of, 341–342
 - pharmacogenomics and, 61, 338–339
 - pharmacokinetics of, 334–339
 - phenobarbital and, 330
 - renal function and, 27
 - sampling of, 340
 - theophylline and, 361
 - valproate and, 372, 373
 - warfarin and, 416, 417

- Phosphate binders, 27
- Pimozide, 76
- Piperacillin, 30, 35
- Piperacillin/tazobactam, 35
- Piroxicam
 - geriatric patient and, 88, 93, 113
 - lithium and, 314
- Pisodironate, 115
- Platinum chemotherapeutics, 312
- Ploglitazone, 113
- Pomalidomide, 329
- Pomegranate juice, 233
- Population parameter estimations,
 - vancomycin, 381
- Posaconazole, 248
- Postoperative mechanical ventilation, 145
- Postpartum, 145
- Potassium supplements, 218
- Pramipexole + cimetidine interaction, 25
- Prasugrel, 417
- Pravastatin
 - antirejection agents and, 218
 - geriatric patient and, 113
- Prazosin, 86, 92
- Prednisolone, 206, 218
- Prednisone, 206, 209–213, 216–220
- Pregabalin
 - antiepileptic properties of, 174, 185–186
 - geriatric patient and, 84
 - valproate and, 373
- Pregnancy
 - aminoglycosides and, 146
 - ethosuzimide and, 255
 - lidocaine and, 296
 - lithium and, 315
 - phenytoin and, 344–345
 - warfarin and, 415
- Prematurity, 146
- Prilocaine, 66
- Primidone
 - antiepileptic properties of, 173, 178, 189
 - carbamazepine and, 232, 233
 - ethosuzimide and, 255
 - valproate and, 372, 373
 - warfarin and, 416
- Probenecid
 - antirejection agents and, 218
 - renal function and, 25
- Procainamide, 90, 93
- Promethazine, 93
- Propafenone
 - digoxin and, 248
 - lidocaine and, 294
 - theophylline and, 361
 - warfarin and, 417
- Propoxyphene, 329
- Propranolol
 - geriatric patient and, 87, 88, 91, 113
 - heparin and, 271
 - lidocaine and, 289
 - phenobarbital and, 329
- Propylthiouracil, 416
- Protamine sulfate, 269–270, 275
- Protease inhibitors
 - antirejection agents and, 219
 - carbamazepine and, 233
 - warfarin and, 416
- Protein binding, 27, 32, 46, 75
 - aminoglycosides and, 127
 - antirejection agents and, 211
 - carbamazepine and, 226
 - ethosuximide and, 252
 - geriatric patient and, 86–88
 - lidocaine and, 288–289
 - phenobarbital and, 325
 - phenytoin and, 336–337
 - theophylline and, 353
 - unfractionated heparin and, 259
 - valproate and, 367
 - vancomycin and, 379
 - warfarin and, 406
- Proton pump inhibitors, 218, 219
- Protriptyline, 157–159, 161, 164–165
- Psychiatry, 61
- Pyridoxine, 329

Q

- Quazepam, 92
- Quetelet's index, 47
- Quetiapine
 - carbamazepine and, 233
 - geriatric patient and, 113
 - phenobarbital and, 329
- Quinapril
 - geriatric patient and, 114
 - renal function and, 30, 35
- Quinidine
 - digoxin and, 248
 - geriatric patient and, 87, 88, 90, 93, 115

- heparin and, 271
 - lidocaine and, 289
 - phenobarbital and, 329
 - warfarin and, 417
 - Quinine
 - phenobarbital and, 329
 - warfarin and, 417
 - Quinolones
 - antirejection agents and, 218
 - theophylline and, 361
 - Quinupristin/dalfopristin, 219
-
- R**
- Rabeprazole, 115
 - Raloxifene, 84
 - Ramipril
 - geriatric patient and, 115
 - renal function and, 30, 35
 - Ranitidine
 - creatinine clearance and, 16
 - geriatric patient and, 115
 - pediatric patient and, 67
 - renal function and, 31, 35
 - valproate and, 372
 - Ranolazine
 - digoxin and, 248
 - phenobarbital and, 329
 - Reboxetine, 26
 - Renal clearance
 - geriatric patient and, 90
 - obesity and, 46–48
 - Renal disease/dysfunction
 - antidepressants and, 168
 - ethosuzimide and, 255
 - lidocaine and, 295
 - warfarin and, 418–419
 - Renal drug transporters, 25
 - Renal elimination, 66–67
 - Renal failure, 344
 - Repaglinide, 115
 - Reserpine, 92
 - Retigabine, 84
 - Ribastigmine, 115
 - Ribavirin, 416
 - Rifabutin, 218, 219
 - Rifampin
 - antiepileptics and, 178
 - carbamazepine and, 233
 - digoxin and, 248
 - pediatric patient and, 68
 - phenobarbital and, 329
 - phenytoin and, 343
 - theophylline and, 361
 - valproate and, 372
 - Rifamycins, 416
 - Rifapentine, 219
 - Rilpivirine, phenobarbital and, 329
 - Risperidone
 - geriatric patient and, 88, 115
 - phenobarbital and, 329
 - Ritonavir
 - antirejection agents and, 219
 - digoxin and, 248
 - phenobarbital and, 329
 - Rivaroxaban
 - geriatric patient and, 115
 - phenobarbital and, 329
 - renal function and, 31
 - Rivastigmine, 84
 - Roberts, A. Joshua, 257–283
 - Rofecoxib, 417
 - Ropinirole, 84, 116
 - Rosiglitazone, 116
 - Rufinamide, 174, 188–189
-
- S**
- Salazar-Corcoran equation, 14–15
 - Salicylates
 - creatinine clearance and, 9
 - geriatric patient and, 87, 88
 - phenytoin and, 343
 - Salsalate, 271
 - Sampling times
 - for aminoglycosides, 137
 - for antidepressants, 165–166
 - for antirejection agents, 215
 - for carbamazepine, 229
 - for digoxin, 244–245
 - for ethosuximide, 254
 - for fosphenytoin, 340
 - for lidocaine, 292–293
 - for lithium, 308–309
 - for phenobarbital, 326–327
 - for phenytoin, 340
 - for theophylline, 358
 - for unfractionated heparin, 266
 - for valproate, 371
 - Saquinavir, 329

- Schwartz formula, 70
- Seizure treatment, 223–238
- Selective serotonin reuptake inhibitors (SSRIs)
antidepressants and, 155
warfarin and, 417
- Selective-serotonin receptor antagonists, 312
- Selegiline
antidepressants and, 156–161, 164
carbamazepine and, 231, 232
- Serotonin norepinephrine reuptake inhibitors (SNRI), 155
- Sertraline
antidepressants and, 156–161, 164–165, 167
geriatric patient and, 116
phenytoin and, 343
- Severe trauma, 295
- Sildenafil, 329
- Simeprevir, 329
- Simvastatin
antirejection agents and, 218
geriatric patient and, 116
- Sirolimus, 205, 207–220
- Sisomicin, 123
Spectinomycin, 123
- 6-mercaptopurine, antirejection agents and, 213, 217
- SLC6A4, 61
- Smoking
antidepressants and, 168
warfarin and, 419
- Sodium channel blockers, 231
- Sodium-containing IV fluids, 314
- Solute carrier (SLC), 57, 58, 59
- Sotalol
geriatric patient and, 88, 93
renal function and, 31
- Special populations, 59–60
- Spinal cord injury, 16, 146
- Spironolactone
creatinine clearance and, 9
digoxin and, 248
geriatric patient and, 92, 116
renal function and, 31
- St. John's wort
antirejection agents and, 219
digoxin and, 248
theophylline and, 360
- Standard dose standard interval (SDSI)
approaches, 125, 131
- START criteria, 92
- Starting dosage, 6
- Statins
antirejection agents and, 218
carbamazepine and, 232
pharmacogenomics and, 57
warfarin and, 417
- Stavudine, 31, 35
- STOPP lists, 92
- Streptomycin, 123, 146
- Subcutaneous absorption, 45
- Sucalfate, 416
- Sulfa antibiotics, 417
- Sulfadiazine, 88
- Sulfamethoxazole
geriatric patient and, 88
pediatric patient and, 75
- Sulfamethoxazole/trimethoprim, 218
- Sulfonamides
pediatric patient and, 69
phenytoin and, 343
- Sulindac
geriatric patient and, 93, 116
lithium and, 314
- Suvorexant, 116
-
- T**
- Tacrine, 361
- Tacrolimus, 205–220
- Tallian, Kimberly B., 323–332
- Tamoxifen
geriatric patient and, 84
phenobarbital and, 329
warfarin and, 417
- Tasaka, Chelsea L., 377–401
- Tasimelteon, 329
- Taxol, 329
- Tedizolid
geriatric patient and, 116
renal function and, 31
- Telaprevir, 329
- Telmisartan, 116
- Temazepam, 88, 89, 92, 116
- Terazosin, 92, 116
- Terbinafine
antirejection agents and, 219
theophylline and, 361
warfarin and, 416

- Testosterone
 geriatric patient and, 86, 93
 warfarin and, 417
- Tetracycline
 digoxin and, 248
 geriatric patient and, 116
 lithium and, 312
 phenobarbital and, 329
 renal function and, 31, 35
 warfarin and, 416
- Theophylline, 351–364
 carbamazepine and, 231
 clearance of, 355
 concentration-related toxicity of, 359–360
 dosage forms of, 352, 354
 dosage range for, 351–352, 353
 dose adjustments for, 359
 dosing strategies for, 356–357
 drug concentration monitoring of, 3, 6–7
 drug–disease state/condition and, 361–362
 drug–drug interactions with, 360–361
 geriatric patient and, 84, 85, 88, 89, 91, 116
 half-life of, 355–356
 lithium and, 312, 314
 pediatric patient and, 71, 72
 pharmacodynamic monitoring of, 358–359
 pharmacokinetics of, 352–355
 phenobarbital and, 329
 renal function and, 27
 salt equivalency for, 354
 sampling times for, 358
 therapeutic monitoring of, 357–358, 359
 therapeutic range for, 357
 time to steady state for, 355–356
- Therapeutic monitoring
 of aminoglycosides, 136–141
 of antidepressants, 155, 165–166
 of antirejection agents, 215
 of carbamazepine, 229–230
 of digoxin, 244–245
 of ethosuximide, 254
 of fondaparinux, 278
 geriatric patient and, 83–119
 of lithium, 308–310, 311
 of low molecular weight heparin, 274
 of phenytoin, 340–341
 of valproate, 371
 of vancomycin, 387
 of warfarin, 411–412
- Therapeutic range, 5, 6
 for aminoglycosides, 164–165
 for antidepressants, 162–163, 164
 for antirejection agents, 214
 for carbamazepine, 229
 for digoxin, 244
 for ethosuximide, 253
 for lidocaine, 292–293
 for lithium, 308
 for low molecular weight heparin, 274
 for phenobarbital, 326–327
 for phenytoin, 340
 for theophylline, 357
 for unfractionated heparin, 264–265
 for valproate, 370–371
 for vancomycin, 385–387, 389
 for warfarin, 410–411
- Thiamine, 86
- Thiazide diuretics, 314
- Thioridazine, 88, 89, 93, 117
- Thioridazine/mesoridazine, 329
- Threshold concentrations, 5
- Thrombolytic agents, 417
- Thrombolytics GPIIb/IIIa antagonists, 271
- Thyroid disease
 antidepressants and, 168
 warfarin and, 419
- Thyroid hormones
 digoxin and, 248
 warfarin and, 416
- Tiagabine
 antiepileptic properties of, 173–174, 179
 geriatric patient and, 84
 phenobarbital and, 329
 valproate and, 373
- Ticagrelor
 geriatric patient and, 117
 phenobarbital and, 329
- Ticarcillin, 75, 76
- Ticarcillin/clavulanate, 35
- Ticlopidine
 geriatric patient and, 84
 phenytoin and, 343
 theophylline and, 361
- Tigecycline
 geriatric patient and, 117
 renal function and, 31
- Time to steady state, 18
 for aminoglycosides, 128
 for antirejection agents, 213
 for carbamazepine, 228
 for digoxin, 241–242
 for ethosuximide, 253
 for lidocaine, 289, 290–291
 for lithium, 305

for phenobarbital, 326
 for phenytoin, 339
 for theophylline, 355–356
 for valproate, 369
 for vancomycin, 381
 for warfarin, 407

Timolol, 117

Tinzaparin, 117, 272, 275

Tirazolam, 189

Tissue bound drugs, 89

Tissue sensitivity, 85

Tizanidine, 329

Tobacco use. *See also* Smoking
 theophylline and, 361
 warfarin and, 419

Tobramycin, 123
 concentration monitoring, interval
 adjustment for, 140
 distribution of, 127
 dosage forms of, 125
 dosing interval for, 132
 geriatric patient and, 117
 inhalation dosing and, 124–125
 maintenance dose for, 124
 pediatric patient and, 74, 75, 76
 pregnancy and, 146
 renal function and, 35

Tolazamide, 117

Tolbutamide, 88, 117

Tolmetin, 93, 117

Tolterodine
 geriatric patient and, 117
 warfarin and, 417

Tolvaptan, 329

Topiramate
 antiepileptic properties of, 173–174, 179–181,
 193
 geriatric patient and, 84, 117
 lithium and, 312
 renal function and, 31
 valproate and, 373

Toremifene, 84, 117

Tramadol
 carbamazepine and, 232
 geriatric patient and, 118
 pediatric patient and, 76
 warfarin and, 417

Trandolapril, 84, 118

Tranlycypromine, 157–160, 164

Trastuzumab, 417

Trazodone
 antidepressants and, 157–159, 161, 164–165,
 167
 geriatric patient and, 87, 118
 phenobarbital and, 329

Triamterine
 creatinine clearance and, 9
 geriatric patient and, 118

Triazolam, geriatric patient and, 84, 88, 92, 118

Triazole antifungals, 329

Tricyclic antidepressants, 155, 163
 ethosuzimide and, 255
 geriatric patient and, 89, 92
 lidocaine and, 289
 phenobarbital and, 329

Trimethobenzamide, 93

Trimethoprim
 creatinine clearance and, 9
 geriatric patient and, 88
 phenytoin and, 343
 renal function and, 31

Trimethoprim-sulfamethoxazole, 118

Trimipramine, 157–159, 161, 164

Tripolidine, 93

Trospectomycin, 123

Tropium, 118

Trough concentration, 136–137, 386, 387–389

Trujillo, Toby C., 285–299

Tyrosine kinase inhibitors, 330

U

Underweight patients, 15, 145

Unfractionated heparin (UFH), 257–283
 dosage forms of, 258
 dosage range for, 257–258
 dosing strategies for, 260–261
 drug–disease state/condition and, 264, 270
 drug–drug interactions of, 270, 271
 pharmacodynamic monitoring of, 268–270
 reversing effect of, 269–270
 therapeutic monitoring of, 266–267
 therapeutic range for, 264–265
 pharmacokinetics of, 258–264

Urea, 144

V

Valproate, 365–375
 carbamazepine and, 231

- dosage forms of, 365, 366
 - dosage range for, 365
 - dosing strategies for, 369–370
 - drug–disease state/condition and, 373
 - drug–drug interactions of, 372
 - pharmacodynamics of, 371–372
 - pharmacokinetics of, 366–370
 - phenytoin and, 343
 - sampling times for, 371
 - therapeutic monitoring of, 371
 - therapeutic range for, 370–371
- Valproic acid**
- antiepileptic properties of, 173, 178–179, 184, 188
 - carbamazepine and, 231, 233
 - drug concentration monitoring of, 3, 5
 - ethosuzimide and, 255
 - geriatric patient and, 118
 - phenobarbital and, 329–330
 - geriatric patient and, 118
- Van Loo, Dean A., 23–39**
- Vancomycin, 377–401**
- aminoglycosides and, 144
 - antirejection agents and, 219
 - area under the curve for, 386, 389–390
 - assay issues with, 395
 - body weight and, 46–47, 48
 - concentration-related toxicity of, 390–391
 - dosage forms of, 378–379
 - dosage range for, 377–378
 - dosing strategies for, 381–385
 - drug concentration monitoring of, 6
 - drug–disease state/condition and, 392–395
 - drug–drug interactions of, 391–392
 - geriatric patient and, 88, 90
 - pediatric patient and, 72, 74, 75
 - pharmacokinetics of, 379–381
 - renal function and, 32, 35
 - therapeutic drug monitoring for, 387
 - therapeutic range for, 385–387
 - trough concentration of, 386, 387–389
- Vecuronium, 232**
- Venlafaxine**
- antidepressants and, 156–161, 164–165, 167–168
 - geriatric patient and, 119
 - renal function and, 31
- Venous thromboembolic disease, 260**
- Verapamil**
- antiepileptics and, 183
 - digoxin and, 248
 - geriatric patient and, 87, 88, 119
- Vigabatrin**
- antiepileptic properties of, 173–174, 189–190
 - renal function and, 31, 35
 - valproate and, 372–373
- Vilazodone**
- antidepressants and, 157–159, 161, 167
 - geriatric patient and, 119
 - phenobarbital and, 330
- Vincristine, 330**
- Vinflunine, 330**
- Vitamin E, 416**
- Vitamin K, 416**
- VKORC1, 60**
- Volume of distribution (V), 27**
- for aminoglycosides, 127, 129
 - for carbamazepine, 226
 - for digoxin, 244
 - for ethosuximide, 252
 - for lidocaine, 287–288
 - for lithium, 304
 - obese patient and, 45–46
 - for phenobarbital, 325
 - for phenytoin, 335–336
 - for theophylline, 354
 - for valproate, 367
 - for vancomycin, 379–380
 - for warfarin, 406
- Vorapaxar, 330**
- Voriconazole**
- phenytoin and, 342–343
 - renal function and, 35
- Vortioxetine**
- antidepressants and, 157–161, 167
 - geriatric patient and, 119
-
- ## W
- Warfarin, 260, 273–274, 403–424**
- dietary supplements and, 418
 - dosage forms of, 404–405
 - dosage range for, 404
 - dosing strategies for, 407–410
 - drug–disease state/condition and, 415, 418–419
 - drug–drug interactions of, 414–415, 416–417
 - flexible initiation of, 408
 - genetics and, 408–409
 - geriatric patient and, 84, 85, 88, 91, 119
 - heparin and, 271
 - pediatric patient and, 69
 - pharmacodynamic monitoring of, 412–413
 - pharmacogenomics of, 60–61

pharmacokinetics of, 405–407
sensitivity factors for, 407
therapeutic monitoring of, 411–412
therapeutic range for, 410–411

Winter, Michael E., 333–349

Wittkowsky, Ann K., 403–424

Wong, Pei Shieen, 173–203, 223–238, 251–256

X,Y,Z

Xanthines, renal function and, 25

Zafirlukast

theophylline and, 361

warfarin and, 417

Zaleplon, 92

Zidovudine, 372

Zidovudine + probenecid, 25

Zileuton, 361

Ziprasidone, 119

Zolpidem, 84, 92, 119

Zonisamide

antiepileptic properties of, 173–174, 179,
184–185

phenobarbital and, 330

